•
Mar 31, 2024
HilleVax Q1 2024 Earnings Report
Reported financial results for the first quarter of 2024 and highlighted recent company progress.
Key Takeaways
HilleVax reported a net loss of $46.8 million for the first quarter of 2024, with $272.7 million in cash, cash equivalents and marketable securities as of March 31, 2024. Topline data from the NEST-IN1 Phase 2B clinical study of HIL-214 in infants is expected in mid-2024.
Cash, cash equivalents and marketable securities totaled $272.7 million as of March 31, 2024.
Research and development expenses for the first quarter 2024 were $26.0 million.
General and administrative expenses for the first quarter 2024 were $8.5 million.
Net loss for the first quarter 2024 was $46.8 million.